Table of Content - U.S., Europe, And China Myelodysplastic Syndrome (MDS) Treatment Marke

In myelodysplastic syndrome (MDS), some of the blood forming cells in bone marrow become abnormal and have problems in forming new and mature blood cells. The immature blood cells called as blasts get stored in the bone marrow and blood, and obstruct the natural function of the hematological system, which results in depletion of healthy red blood cells, platelets, and white blood cells. It is usually observed in geriatric population and more often in older men compared to women. For instance, according to the American Society of Clinical Oncology (ASCO), age plays an important role in the occurrence of myelodysplastic syndrome, as most of the people diagnosed with the disease are of age 65 and older.

Moreover, increasing possibility of MDS to further progress into rapidly growing cancer of bone marrow cells called acute myeloid leukemia (AML), leads to increasing efforts by key players develop highly effective therapies for MDS treatment. Furthermore, rising awareness about MDS and its symptoms with advanced methods and techniques for early diagnosis and treatment for various forms of the MDS is expected to drive the market growth over the forecast period. Increased understanding of the pathology of the syndrome is directing the research towards developing more specialized and symptom based treatments with effective costs, so that MDS patients can avail these benefits.

Market Dynamics

The increasing prevalence of MDS is expected to drive the demand of drugs used for the treatment of MDS, thereby expected to drive the U.S., Europe, and China myelodysplastic syndrome treatment market growth over the forecast period. Incidence rate for myelodysplastic syndrome has witnessed an increase in the last few years as the average population is ageing every consecutive year. For instance, according to the American Cancer Society report 2018, over 10,000 new cases of MDS occur in the U.S. every year, which is expected to boost the market growth.

Key features of the study:

This report provides in-depth analysis of the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and Strategies
Key companies covered as a part of this study include Bristol Myers Squibb, Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Acceleron Pharma, Inc., Onconova Therapeutics, Inc., Aprea Therapeutics, Geron, Fibrogen, Inc., Jazz Pharmaceuticals, AbbVie Inc., Lixte Biotechnology Holdings, Inc., Gilead Sciences, CrystalGenomics, Inc., ALX Oncology Inc., and Keros Therapeutics.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market

Detailed Segmentation:

U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Drugs:
- Lenalidomide
- Decitabine
- Azacitidine
- Luspatercept
- Phase 3 Drugs
U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Route of Administration:
- Injection
- Oral
U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Country/Region:
- U.S.
  - By Drugs
    - Lenalidomide
    - Decitabine
    - Azacitidine
    - Luspatercept
    - Phase 3 Drugs
  - By Route of Administration
    - Injection
    - Oral
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Europe
  - By Drugs
    - Lenalidomide
    - Decitabine
    - Azacitidine
    - Luspatercept
    - Phase 3 Drugs
  - By Route of Administration
    - Injection
    - Oral
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- U.K.
  - By Drugs
    - Lenalidomide
    - Decitabine
    - Azacitidine
    - Luspatercept
    - Phase 3 Drugs
  - By Route of Administration
    - Injection
    - Oral
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Germany
  - By Drugs
    - Lenalidomide
    - Decitabine
    - Azacitidine
    - Luspatercept
    - Phase 3 Drugs
  - By Route of Administration
    - Injection
    - Oral
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Italy
  - By Drugs
    - Lenalidomide
    - Decitabine
    - Azacitidine
    - Luspatercept
    - Phase 3 Drugs
  - By Route of Administration
    - Injection
    - Oral
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- France
  - By Drugs
    - Lenalidomide
    - Decitabine
    - Azacitidine
    - Luspatercept
    - Phase 3 Drugs
  - By Route of Administration
    - Injection
    - Oral
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Spain
  - By Drugs
    - Lenalidomide
    - Decitabine
    - Azacitidine
    - Luspatercept
    - Phase 3 Drugs
  - By Route of Administration
    - Injection
    - Oral
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Russia
  - By Drugs
    - Lenalidomide
    - Decitabine
    - Azacitidine
    - Luspatercept
    - Phase 3 Drugs
  - By Route of Administration
    - Injection
    - Oral
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- Rest of Europe
  - By Drugs
    - Lenalidomide
    - Decitabine
    - Azacitidine
    - Luspatercept
    - Phase 3 Drugs
  - By Route of Administration
    - Injection
    - Oral
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
- China
  - By Drugs
    - Lenalidomide
    - Decitabine
    - Azacitidine
    - Luspatercept
    - Phase 3 Drugs
  - By Route of Administration
    - Injection
    - Oral
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
Company Profiles
- Bristol Myers Squibb*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Reddy's Laboratories Ltd.
- Sun Pharmaceutical Industries Limited
- Cipla Limited
- Acceleron Pharma, Inc.
- Onconova Therapeutics, Inc.
- Aprea Therapeutics
- Geron
- Fibrogen, Inc.
- Jazz Pharmaceuticals
- AbbVie Inc.
- Lixte Biotechnology Holdings, Inc.
- Gilead Sciences
- CrystalGenomics, Inc.
- ALX Oncology Inc.
- Keros Therapeutics.

“*” marked represents similar segmentation in other categories in the respective section.

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Drugs
  - Market Snapshot, By Route of Administration
  - Market Snapshot, By Distribution Channel
  - Market Snapshot, By Region
  - Market Opportunity Map
U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Pipeline Analysis
- Regulatory Scenario
- Market Trends
- Product Launch
- PEST Analysis
- Key Developments
- Collaborations & Acquisitions
- Epidemiology
- Brand Analysis
U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market - Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Supply Chain Analysis
- Government Initiatives
U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Drugs, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
- Introduction
  - Market Share Analysis, 2020 and 2027(%)
  - Y-o-Y Growth Analysis, 2017 – 2027
  - Segment Trends
- Lenalidomide
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
- Decitabine
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
- Azacitidine
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
- Luspatercept
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
- Phase 3 Drugs
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Route of Administration, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
- Introduction
  - Market Share Analysis, 2020 and 2027(%)
  - Y-o-Y Growth Analysis, 2017 – 2027
  - Segment Trends
- Injection
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
- Oral
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million
U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Distribution Channel, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
- Introduction
  - Market Share Analysis, 2020 and 2027(%)
  - Y-o-Y Growth Analysis, 2017 – 2027
  - Country at Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (Value in US$ Mn) and (Volume in Units)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (Value in US$ Mn) and (Volume in Units)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (Value in US$ Mn) and (Volume in Units)
U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Country/Region, 2016 – 2027(Value in US$ Mn) and (Volume in Units)
- Introduction
  - Market Share Analysis, 2020 and 2027(%)
  - Y-o-Y Growth Analysis, 2017 – 2027
  - Country/Regional Trends
- U.S.
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
- Europe
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
    - U.K.
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
    - Germany
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
    - Italy
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
    - France
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
    - Spain
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
    - Russia
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
    - Rest of Europe
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
      - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
- China
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2016 – 2027, (Value in US$ Mn) and (Volume in Units)
Company Profiles
- Bristol Myers Squibb
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Otsuka Pharmaceutical Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Mylan N.V.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Reddy's Laboratories Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Sun Pharmaceutical Industries Limited
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Cipla Limited
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Acceleron Pharma, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Onconova Therapeutics, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Aprea Therapeutics
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Geron
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Fibrogen, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Jazz Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Lixte Biotechnology Holdings, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Gilead Sciences
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- CrystalGenomics, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- ALX Oncology Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Keros Therapeutics
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
Section
- Research Methodology
- About us

*Browse 77 market data tables and 41 figures on "myelodysplastic syndrome (MDS) treatment market” - U.S., Europe, and China forecast to 2027

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount